Gutiérrez-Castrellón P, Mora-Magaña I, Díaz-García L, Jiménez-Gutiérrez C, Arzola-Paniagua A

Language: Spanish
References: 25
Page: 158-166
PDF size: 166.11 Kb.

ABSTRACT

More than 80% of the pregnant women, in one moment of the gestation have nausea and vomiting, than can produce important complications like deshydratation, hospital internment, and affectation of the quality of life. There are controversies about the safety of the combination of doxylamine + pyridoxine for the treatment of the nausea and vomiting of pregnancy (NVP). Objective: To evaluate the efficacy and safety of the combination of doxylamine + pyridoxine for the treatment of NVP using the methodological tool of a systematic review. Materials and methods: For the systematic review we include case-control studies, cohort's studies, and controlled trials, performed in pregnant women with NVP and that were treatment with doxylamine + pyridoxine. We considered the number of congenital defects as the principal outcome variable. We made the systematic review using the following data bases: PubMed (1966 to may 2009), Embase (1988 to may 2009), LILACS (1990 to may 2009), ARTEMISA (review of the 11ª edition to December 2004), Cochrane controlled trials register, Bandolier y DARE. The statistical analysis was made with the calculation of relative risk (RR) and 95% confidence interval (CI 95%) with the Mantel-Hanezel model. Results: There was no risk increase of congenital defects in children born of women with NVP treated with the combination of doxylamine + pyridoxine. The RR identified for all congenital defects was 0.97(IC95% de 0.92 a 1.02), p = 0.168; for cardiovascular defects the RR was 0.92 (CI95% 0.80-1.05), for neural tube defects the RR was 0.99 (CI95% 0.78-1.26), and for urinary defects the RR was 0.99 (CI95% 0.8-1.20). The administration of doxylamine + pyridoxine reduced the risk of NVP persistence with a RR of 0.55 (CI95% 0.41-0.74), p ‹ 0.01). Conclusions: The systematic review showed that the administration of doxylamine + pyridoxine has a beneficial effect on the reduction of NVP manifestations, with a high safety to be used during pregnancy.

REFERENCES

1. Bishai R, Mazzotta P, Atanackovic G, Levichek Z, Pole M, Magee LA et al. Critical appraisal of drug therapy for nausea and vomiting of pregnancy: II. Efficacy and safety of diclectin (doxylamine-B6). Can J Clin Pharmacol 2000; 7: 138-43.

2. Mazzotta P, Magee LA. A risk-benefit assessment of pharmacological and nonpharmacological treatments for nausea and vomiting of pregnancy. Drugs 2000; 59: 781-800.

3. Serafin WE, Babe KS. H1-receptors antagonists. In: Gilman AG, Hardman JG, Limbrid LE, eds. Goodman & Gilman’s the pharmacology bases of therapeutics. 14o Ed. New York: McGraw-Hill companies 1996; pag:586-592.

4. Tani AS. Antihistamines. In: Olson KR, ed. Poisoning & Drug overdose. Norway: Appleton & Lange 1998: 78-9.

5. Gielsdorf W, Schubert K. Biotransformation of doxylamine: isolation, identification and synthesis of some metabolites. J Clin Chem Clin Biochem 1981; 19: 485-90.

6. Ganes DA, Midha KK. Identification in in vivo acetylation pathway for N-dealkylated metabolites of doxylamine in humans. Xenobiotica 1987; 17: 993-9.

7. Friedman H, Greenblatt DJ. The pharmacokinetics of doxylamine: use of automated gas chromatography with nitrogen-phosphorus detection. J Clin Pharmacol 1985; 25: 448-51.

8. Rowland JM, Slikker W Jr, Holder CL, Denton R, Prahalada S, Young JF et al. Pharmacokinetics of doxylamine given as Bendectin in the pregnant monkey and baboon. Reprod Toxicol 1989; 3: 197-202.

9. Slikker W Jr, Holder CL, Lipe GW, Bailey JR, Young JF. Pharmacokinetics of doxylamine, a component of Bendectin, in the rhesus monkey. Reprod Toxicol 1989; 3: 187-96.

10. Shideler CE. Vitamin B6: an overview. Am J Med Technol 1983; 49: 17-22.

11. Gregory JF 3rd. Bioavailability of vitamin B-6. Eur J Clin Nutr 1997; 51: S43-8.

12. Shideler CE. Vitamin B6: an overview. Am J Med Technol 1983;49: 17-22.

13. Merrill AH Jr, Henderson JM. Vitamin B6 metabolism by human liver. Ann N.Y. Acad Sci 1990;585:110-7.

14. Bender DA. Vitamin B6 requirements and recommendations. Eur J Clin Nutr 1989; 43: 289-309.

15. Zempleni J, Kübler W. The utilization of intravenously infused pyridoxine in humans. Clin Chim Acta 1994; 229: 27-36.

16. Einarson TR, Leeder JS, Koren G. A method for meta-analysis of epidemiological studies. Drug Intell Clin Pharm 1988; 22: 813-24.

17. McKeigue PM, Lamm SH, Linn S, Kutcher JS. Bendectin and birth defects: I. A meta-analysis of the epidemiologic studies. Teratology 1994; 50: 27-37.

18. Roumiana S, Bonevau CA, Moore LB, Lee-Yang Wong, Erickson JD. Nausea during pregnancy and congenital heart defects: a population-based case-control study. Am J Epidemiol 1999; 149: 717-25.

19. Atanackovic G, Navioz Y, Moretti ME, Koren G. The safety of higher than standard dose of doxylamine-pyridoxine (Diclectin) for nausea and vomiting of pregnancy. J Clin Pharmacol 2001; 41: 842-5.

20. Laura A. Magee, MD, Mazzotta P, Gideon K. Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP). Am J Obstet Gynecol 2002; 186: S256-61.

21. Jewell D, Young G. Interventions for nausea and vomiting in early pregnancy. Cochrane Database Sys Rev 2003; 4: CD000145. DOI: 10.1002/14651858.CD000145

22. Boskovic R, Rudic N, Danieliewska-Nikiel B, Navioz Y, Koren G. Is lack of morning sickness teratogenic? A prospective controlled study. Birth Defects Res A Clin Mol Teratol (Part A) 2004; 70: 528-30.

23. Medalie JH. Relationship between nausea and/or vomiting in early pregnancy and abortion. Lancet 1957; 273: 117-9.

24. Gasdby R, Barnie-Adshead AM, Jagger C. A prospective study of nausea and vomiting during pregnancy. Br J Gen Pract 1993; 43: 245-8.

25. Whitehead SA, Andrews PL, Chamberlain GV. Characterization of nausea and vomiting in early pregnancy: a survey of 1,000 women. J Obstet Gynaecol 1992;12: 364-9.